mr058666-web

Merck Q2 results beat analyst estimates

pharmafile | August 4, 2016 | News story | Medical Communications, Sales and Marketing Merck, financial results 

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, depreciation and amortisation reaching €1.16 billion, a rise of 29%.

The company’s successes were boosted by its acquisition of Sigma-Aldrich in November 2015 and demand for its fonal-f fertility treatment after the recall of rival product bravelle in the US when it was found to fall short of potency requirements.

As a result, the firm has raised its forecasts from approximately €1.49 billion to €15.1 billion.

Healthcare revenue fell by 2.7% to €1.8 billion, but profits climbed to €557 million, an increase of 16%.  

Merck is currently looking at its $2 billion collaboration with Pfizer developing cancer therapies which is expected to grow the company next year when the first treatments become available to patients, being the first new medicines from the company in 10 years.

Matt Fellows

Related Content

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

Merck, known as MSD outside of the US and Canada, has announced that the US …

Merck to acquire EyeBio for an upfront $1.3bn

Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced …

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

Merck, known as MSD outside of the US and Canada, has announced results from the …

Latest content